Hypopigmented Mycosis Fungoides: Loss of Pigmentation Reflects Antitumor Immune Response in Young Patients.
Amelia Martínez VillarrealJennifer GantchevFrançois LagacéAugustin BaroletDennis SassevilleNiels OdumYann Vincent Charli-JosephAmparo Hernández SalazarIvan V LitvinovPublished in: Cancers (2020)
Hypopigmented mycosis fungoides (HMF) is a form of cutaneous T-cell lymphoma (CTCL), a heterogeneous group of extranodal non-Hodgkin's lymphomas. HMF has a unique set of defining features that include light colored to achromic lesions, a predilection for darker skin phototypes, an early onset of disease, and predominance of CD8+ T-cells, among others. In the current review, we detail the known pathways of molecular pathogenesis for this lymphoma and posit that an active Th1/cytotoxic antitumor immune response in part explains why this variant is primarily seen in children/adolescents and young adults, who do not exhibit signs of immunosenescence. As a result of this potent cytotoxic response, HMF patients experience mostly favorable overall prognosis, while hypopigmentation may in fact represent a useful surrogate marker of cytotoxic immunity targeting the malignant cells. Understanding the molecular processes behind the specific features that define HMF may lead to improved diagnostic accuracy, personalized prognosis by risk stratification, and improved management of HMF. Moreover, improving our knowledge of HMF may aid our further understanding of other cutaneous lymphomas.
Keyphrases
- immune response
- early onset
- end stage renal disease
- ejection fraction
- newly diagnosed
- chronic kidney disease
- healthcare
- peritoneal dialysis
- prognostic factors
- induced apoptosis
- late onset
- patient reported outcomes
- dendritic cells
- diffuse large b cell lymphoma
- signaling pathway
- inflammatory response
- patient reported
- soft tissue
- toll like receptor
- single molecule
- middle aged
- cell cycle arrest